Andiroba oil and nanoemulsion (Carapa guianensis Aublet) reduce lesion severity caused by the antineoplastic agent doxorubicin in mice.

Autor: Melo KM; Laboratório de Citogenética, Centro de Estudos Avançados da Biodiversidade, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brazil; Universidade Federal Rural da Amazônia, Campus Tomé Açu, Tomé Açu, PA, Brazil. Electronic address: karina.melo@ufra.edu.br., Oliveira LFS; Laboraratório de Imunohistoquímica e Biologia do Desenvolvimento, Instituto de Ciências Biológicas, Universidade Federal do Pará, Brazil. Electronic address: oliveira.lfs2@gmail.com., da Rocha RM; Laboratório de Ultraestrutura Celular e Técnicas Histológicas, Universidade Federal do Pará, Belém, PA, Brazil. Electronic address: rmrocha.ufpa@icloud.com., Ferreira MAP; Laboraratório de Imunohistoquímica e Biologia do Desenvolvimento, Instituto de Ciências Biológicas, Universidade Federal do Pará, Brazil. Electronic address: auxi@ufpa.br., Fascineli ML; Laboratório de Genética Toxicológica, Universidade de Brasília, Brasília, DF, Brazil. Electronic address: fascineli@yahoo.com.br., Milhomem-Paixão SSR; Instituto Federal de Educação, Ciência e Tecnologia do Goiás, Campus Valparaiso de Goiás, Brazil. Electronic address: susanamilhomem@yahoo.com.br., Grisolia CK; Laboratório de Genética Toxicológica, Universidade de Brasília, Brasília, DF, Brazil. Electronic address: grisolia@unb.br., Santos AS; Laboratório de Investigação Sistemática em Biotecnologia e Biodiversidade Molecular, Universidade Federal do Pará, Belém, PA, Brazil. Electronic address: alberdan@ufpa.br., Salgado HLC; Laboratório de Investigação Sistemática em Biotecnologia e Biodiversidade Molecular, Universidade Federal do Pará, Belém, PA, Brazil. Electronic address: hugocsal.hs@gmail.com., Muehlmann LA; Laboratório de Nanobiotecnologia, Universidade de Brasília, Brasília, DF, Brazil. Electronic address: luismuehlmann88@gmail.com., Azevedo RB; Laboratório de Nanobiotecnologia, Universidade de Brasília, Brasília, DF, Brazil. Electronic address: razevedo@unb.br., Pieczarka JC; Laboratório de Citogenética, Centro de Estudos Avançados da Biodiversidade, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brazil. Electronic address: juliopieczarka@gmail.com., Nagamachi CY; Laboratório de Citogenética, Centro de Estudos Avançados da Biodiversidade, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brazil. Electronic address: cleusanagamachi@gmail.com.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Jun; Vol. 138, pp. 111505. Date of Electronic Publication: 2021 Mar 24.
DOI: 10.1016/j.biopha.2021.111505
Abstrakt: Doxorubicin (DOX) is an anthracycline antibiotic used in the fight against many types of cancer. Although it is quite effective for this purpose, its clinical use is limited by its severe side effects, highlighting the relevance of efforts to identify substances that act to minimize these effects. In this work, we sought to verify the ability of andiroba oil (AO) and a nanoemulsion of andiroba oil (AN) to lessen the side effects of DOX. The animals were separated into 7 groups with 6 animals each: mice treated with AO (2000 mg/kg), AN (2000 mg/kg), the antineoplastic agent DOX (40 mg/kg), AO+DOX, AN+DOX and solvent controls was used of negative control (corn oil and nanoemulsion surfactant). AO and AN were administered for 14 consecutive days orally by gavage and on the 13th day, applied DOX by intraperitoneal route (i.p.), in order to evaluate the protective potential of andiroba. The animals were euthanized on the 15th day. Hematological, biochemical, histological, and immunohistochemical parameters were analyzed. Andiroba reduced several aspects of the severity of lesions caused by DOX, decreasing hematotoxicity and the severity of histological changes in the liver and kidneys, and reducing the frequency of apoptotic cell death. In many cases, AN showed greater efficacy than AO alone, reflecting the feasibility of using this nanotechnology to improve the pharmacokinetics of lipid compounds in the body. The study sheds new light on the therapeutic benefits of andiroba and suggests new ways for investigating how the quantity and quality of lipid compounds affect exposed organisms.
(Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: